MedTrace Logo

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

NCT03300765 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-10-03

No results posted yet for this study

Summary

To determine the efficacy and safety of intensity modulated radiation therapy combined with apatinib for inoperable or iodine refractory thyroid cancer.

Conditions

Interventions

DRUG

Apatinib

Apatinib will be used as induction therapy in experimental arm.

RADIATION

Intensity modulated radiation therapy

Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.

Sponsors & Collaborators

  • Xiayun He, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-07-01
Completion
2020-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03300765 on ClinicalTrials.gov